期刊
HEPATOLOGY RESEARCH
卷 52, 期 1, 页码 67-74出版社
WILEY
DOI: 10.1111/hepr.13712
关键词
bevacizumab; hepatocellular carcinoma; immune checkpoint inhibitor; non-alcoholic steatohepatitis; atezolizumab; vascular endothelial growth factor
资金
- Ministry of Education, Culture, Sports, Science and Technology [21K07912]
- Grants-in-Aid for Scientific Research [21K07912] Funding Source: KAKEN
Immune checkpoint inhibitors have shown benefits in cancer treatment across different organs, but may have limited efficacy in NASH-related HCC patients. Combining anti-VEGF agents could potentially enhance the therapeutic effect of immune checkpoint inhibitors for NASH-related HCC.
Immunotherapy with immune checkpoint inhibitors has been shown to be beneficial for cancers originating from various organs. In May 2020, combination therapy with anti-programmed death-ligand 1 antibody atezolizumab and anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was approved as a novel first-line systemic therapy for hepatocellular carcinoma (HCC). The number of patients with HCC not caused by hepatitis virus infection (non-viral HCC), including non-alcoholic steatohepatitis (NASH)-related HCC, has been increasing in recent years. Recently, Pfister and colleagues reported that immune checkpoint inhibitors may exhibit limited efficacy against NASH-related HCC, based on basic research and clinical data. This review will discuss the mechanism of impaired tumor immune surveillance in NASH and analyze the results of previously published clinical trials of immune checkpoint inhibitors to investigate whether patients with non-viral HCC are less likely to benefit from immunotherapy with immune checkpoint inhibitors. Furthermore, we also discuss the possibility of enhancing the therapeutic effect of immune checkpoint inhibitors for NASH-related HCC by combining anti-VEGF agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据